Addendum: Sequencing of  BRCA1/2 -alterations using NGS-based technology: annotation as a challenge

Silvana Ebner; Ria Winkelmann; Saskia Martin; Jens Köllermann; Peter J. Wild; Melanie Demes

doi:10.18632/oncotarget.28483

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Sequencing of BRCA1/2-alterations using NGS-based technology: annotation as a challenge

PDF | How to cite

Oncotarget. 2023; 14:788-788. https://doi.org/10.18632/oncotarget.28483

Metrics: PDF 319 views | ?

Silvana Ebner¹, Ria Winkelmann¹, Saskia Martin¹, Jens Köllermann¹, Peter J. Wild^1,2, and Melanie Demes^1,2

¹Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany
²Wildlab, University Hospital MVZ GmbH, Frankfurt am Main, Germany

Published: August 30, 2023

Copyright: © 2023 Ebner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: No external funding was obtained.

Original article: Oncotarget. 2022; 13:464-475. DOI: https://doi.org/10.18632/oncotarget.28213.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28483

Publication Alerts

Addendum:

Addendum: Sequencing of BRCA1/2-alterations using NGS-based technology: annotation as a challenge